Novartis Venture Fund
About
Our primary focus is on the development of novel therapeutics and platforms. In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capital efficiency in the program. We invest in North America, Europe, Israel and Asia/Pacific with approximately USD 800 million under management in committed capital and more than 24 portfolio companies.
Key facts
- Website
- novartis.com
- Type
- Corporate Venture Capital
- Headquarters
- Switzerland
- Funds raised
- $800M
- Portfolio companies
- 12
- Stages
- Series BSeries F
- Cheque size
- $5M to $30M
- Sector focus
- HealthcareDrug DevelopmentGenomicsNext Generation SequencingBiotech
Recent investments
| Date | Company | Round | Amount |
|---|---|---|---|
| 8 Apr 2026 | Sidewinder Therapeutics | Series B | $137M |
| 23 Aug 2023 | FORE Biotherapeutics | Series D | $75M |
| 21 Sept 2020 | FORE Biotherapeutics | Series C | $57M |
| 28 May 2019 | Ayala Pharmaceuticals | Series B | $30M |
| 19 Jun 2017 | Gamida Cell | Series G | $40M |
| 15 Oct 2015 | Gamida Cell | Series F | $5M |
| 19 Aug 2014 | Gamida Cell | Series F | $35M |
Test your Ahrefs DR
The backlink strength of a domain, on the Ahrefs 0 to 100 scale. About a minute.
Frequently asked
What companies has Novartis Venture Fund invested in?
Novartis Venture Fund has invested in Sidewinder Therapeutics, FORE Biotherapeutics, Ayala Pharmaceuticals, Gamida Cell, Beam Therapeutics and 7 more.
SEC filings, insider activity, nonprofit links and pay benchmarks for Novartis Venture Fund:
